Implication of CYP24A1 Splicing in Breast Cancer

被引:12
作者
Scheible, Chimi [1 ]
Thill, Marc [2 ]
Baum, Sascha [3 ]
Solomayer, Erich [3 ]
Friedrich, Michael [1 ]
机构
[1] Helios Klinikum Krefeld, Klin Frauenheilkunde & Geburtshilfe, D-47805 Krefeld, Germany
[2] Agaples Markus Krankenhaus, Klin Frauenheilkunde & Geburtshilfe, D-60431 Frankfurt, Germany
[3] Univ Klinikum Saarlandes, Klin Frauenheilkunde & Geburtshilfe, D-66424 Homburg, Germany
关键词
Vitamin D-3; 24-hydroxylase; splicing variants; MCF-7; MCF-10; breast tissue; VITAMIN-D; D-3; 1,25-DIHYDROXYVITAMIN-D; METABOLISM; MECHANISM; VARIANTS; RISK; D-3-1-ALPHA-HYDROXYLASE; EXPRESSION; GROWTH;
D O I
10.2174/18715206113139990311
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
The expression of CYP27B1 or vitamin D 1 alpha-hydroxylase (1 alpha-OHase) and CYP24A1 in specific tissues may act as the central part between 25-hydroxyvitamin D [25(OH)D] serum levels and the anticancer effects of1 alpha,25-dihydroxyvitamin D [1 alpha,25(OH)(2)D-3], alternative splicing of these enzymes may affect their biological functions. Here, we describe the expression of CYP24A1 and its splicing variants detected in breast cells and tissues. Manifestation of CYP24A1 mRNA was measured by RT-PCR followed by western blot analysis for protein expression. In MCF-7 cells, the expression of CYP24A1 protein was reduced by about 57% compared to MCF-10F cells. Western blot analysis revealed a signal band at 56 kDa, with additional bands detected at 42 and 44 kDa. The expression of CYP24A1 mRNA was reduced by about 58% in breast cancer tissues. We found only one signal in the benign tissues at 56 kDa in western blot, whereas in malignant tissue, an additional band was detected at 40kDa. Our results suggest that alternative splicing of CYP24A1 may lead to a catalytically dysfunctional enzyme.
引用
收藏
页码:109 / 114
页数:6
相关论文
共 37 条
[1]   Quantitative mapping of amplicon structure by array CGH identifies CYP24 as a candidate oncogene [J].
Albertson, DG ;
Ylstra, B ;
Segraves, R ;
Collins, C ;
Dairkee, SH ;
Kowbel, D ;
Kuo, WL ;
Gray, JW ;
Pinkel, D .
NATURE GENETICS, 2000, 25 (02) :144-146
[2]   Expression of VDR and CYP24A1 mRNA in human tumors [J].
Anderson, MG ;
Nakane, M ;
Ruan, XA ;
Kroeger, PE ;
Wu-Wong, JR .
CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2006, 57 (02) :234-240
[3]   Expression of 25 hydroxyvitamin D3-1α-hydroxylase in human endometrial tissue [J].
Becker, Steffi ;
Cordes, Tim ;
Diesing, Dagmar ;
Diedrich, Klaus ;
Friedrich, Michael .
JOURNAL OF STEROID BIOCHEMISTRY AND MOLECULAR BIOLOGY, 2007, 103 (3-5) :771-775
[4]   Plasma 25-hydroxyvitamin D and 1,25-dihydroxyvitamin D and risk of breast cancer [J].
Bertone-Johnson, ER ;
Chen, WY ;
Holick, MF ;
Hollis, BW ;
Colditz, GA ;
Willett, WC ;
Hankinson, SE .
CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION, 2005, 14 (08) :1991-1997
[5]   New insights into the mechanisms of vitamin D action [J].
Christakos, S ;
Dhawan, P ;
Liu, Y ;
Peng, XR ;
Porta, A .
JOURNAL OF CELLULAR BIOCHEMISTRY, 2003, 88 (04) :695-705
[6]  
Colston KW, 2006, ANTICANCER RES, V26, P2573
[7]   Mechanisms implicated in the growth regulatory effects of vitamin D in breast cancer [J].
Colston, KW ;
Hansen, CM .
ENDOCRINE-RELATED CANCER, 2002, 9 (01) :45-59
[8]   Vitamin D, calcium, and breast cancer risk: A review [J].
Cui, Yan ;
Rohan, Thomas E. .
CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION, 2006, 15 (08) :1427-1437
[9]  
Diesing D, 2006, ANTICANCER RES, V26, P2755
[10]   gamma-interferon-induced resistance to 1,25-(OH)(2)D-3 in human monocytes and macrophages: A mechanism for the hypercalcemia of various granulomatoses [J].
Dusso, AS ;
Kamimura, S ;
Gallieni, M ;
Zhong, M ;
Negrea, L ;
Shapiro, S ;
Slatopolsky, E .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 1997, 82 (07) :2222-2232